Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study.

This mixed-methods study sought to identify pharmacotherapy preferences among 40 noninsulin-treated adults with type 2 diabetes receiving care at two U.S. health care systems. Participants ranked by relative importance various health outcomes and medication attributes and then contextualized their rankings. Most participants ranked blindness (63%), death (60%), heart attack (48%), and heart failure (48%) as the most important health outcomes and glucose-lowering efficacy (68%) as the most important medication attribute, followed by oral administration (45%) and lack of gastrointestinal side effects (38%).

©2024 by the American Diabetes Association.

G.E.U. has received unrestricted support for research studies to Emory University from Abbott, Bayer, and Dexcom and is on the advisory board of directors for GlyCare. R.J.G. is supported in part by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and has received unrestricted research support to Emory University from Dexcom, Elil Lilly, and Novo Nordisk and consulting fees from Bayer, Boehringer, Eli Lilly, Novo Nordisk, Pfizer, Sanofi, and Weight Watchers, all of which was unrelated to this work. R.G.M. has received support from NIDDK, the National Institute on Aging, the National Center for Advancing Translational Sciences, and AARP for projects unrelated to this work. She also serves as a consultant to Emmi (Wolters Kluwer) for developing patient education materials related to prediabetes and diabetes. No other potential conflicts of interest relevant to this article were reported.